Big pharma team up to form Asian cancer R&D firm
This article was originally published in Scrip
Executive Summary
Lilly, Pfizer and Merck & Co have agreed to collaborate in one key emerging market to tackle lung and gastric cancers. The companies have formed a not-for-profit company to expedite research and to improve treatments for the most commonly diagnosed cancers in Asia.